Brainsway Deep TMS Therapy - for Brain Disorder Treatment

A Randomized Sham-Controlled Study of H-Coil Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Late-Life Depression

University of Toronto, Faculty of Medicine, Centre for Addiction & Mental Health, Canada

20 March 2013

Depression is a prevalent illness in late-life and it contributes to functional morbidity and mortality. Up to 84% of patients treated for late-life depression (LLD) either do not respond to treatment or respond and then relapse. Pharmacological strategies for managing treatment resistance in the elderly are problematic due to higher sensitivity to medication adverse effects and drug-drug interactions. Electroconvulsive therapy (ECT) has an excellent track record in treatment-resistant late-life depression (TRLLD). However, many patients refuse treatment with ECT due to social stigma and the risk of marked memory impairment. Over the past decade, deep transcranial magnetic stimulation (Deep TMS) has been shown to be effective and well tolerated for treatment-resistant depression (TRD) in younger adults. However, only few studies, with limited sample sizes, have evaluated Deep TMS for TRLLD. Some studies have concluded that older age predicts inferior outcome, due to the presence of prefrontal cortical atrophy, a common finding in older patients with LLD. The inferior outcomes can be explained as follows: the magnetic field produced by the standard rTMS figure-8 coil provides only superficial cortical stimulation. In the presence of age-related prefrontal atrophy, the distance from the scalp to the cortex increases and the magnetic field cannot penetrate the cortex deep enough to produce therapeutic effects. Brainsway® Ltd. has developed a patented Deep TMS coil called the H-Coil that provides far greater depth of penetration. This H-Coil has the potential to overcome age-related prefrontal atrophy and to stimulate brain structures involved in LLD. We propose to assess the efficacy and tolerability of H-Coil Deep TMS in TRLLD using a randomized-controlled trial.  The proposed research could have a major impact on TRLLD, a significant and growing public-health problem in Canada and the Western world.

Contact: Daniel M. Blumberger MD, MSc, FRCPC Tel: 416-535-8501 x 33662             

Email: daniel.blumberger@camh.ca

Principal Investigator: Daniel M. Blumberger MD, MSc, FRCPCZ.  Jeff Daskalakis MD, PhD, FRCPC


© Brainsway Ltd.® 2014 | All rights reserved. Patients Portal · Brainsway Deep TMS · FDA Clearance · Disclaimer · Privacy Policy · Terms of Use